Medical Properties Trust, Inc.

Reported second-quarter 2026 normalized FFO was $0.15 per share, compared with $0.14 in the prior quarter. G&A was higher year over year due mainly to stock compensation tied to cash-settled awards and depreciation on the headquarters building placed into service in Q1 2026, and the company impaired about $17 million in working capital loans, mainly tied to two Steward replacement tenants in the Midwest. On operations, total portfolio EBITDARM coverage was steady; general acute coverage was 2.8x, post-acute coverage was 2.4x, and behavioral coverage was 1.4x. Management said the refinancing will retire all 2026 maturities and the remainder of the 2027 notes in two steps, leaving no debt maturities in 2026 or 2027 and only about $600 million due in June 2028; expected liquidity is about $1.1 billion based on near-term asset sales. The new secured notes carry a 9.25% coupon and a 5.5-year term, prepayable after 2 years.

Ed Aldag framed the quarter around capital structure repair and portfolio durability. He emphasized that the refinancing extends $2.4 billion of debt maturities to 2032, reduces near-term refinancing risk, and supports a balanced capital allocation strategy. He also highlighted strong post-acute growth, stability in general acute, and continuing demand for rehabilitation services, while acknowledging pressure in behavioral health and the UK from NHS funding constraints. His tone was constructive and confident, especially around asset values, Switzerland, and the company’s ability to clear the runway to reach over $1 billion of annualized cash rent by year-end.

Steve Hamner focused on the mechanics of the refinancing and the balance sheet. He said step 1 is the issuance of $2.4 billion in secured notes, used to repay the €500 million 2026 maturity and about $738 million of 2027 notes, while step 2 will complete repayment of the rest of the 2027s, add a new multiyear revolver, and repay the $200 million term loan due in June 2027. He said the company will have no debt maturing in 2026 or 2027, about $600 million due in June 2028, and about $1.1 billion of expected liquidity from asset sales, with bond covenant coverage improving from a minimum 1.5x to as high as 300% depending on liquidity deployment. He also pointed to asset-sale proceeds, including about $140 million from Infracore and about $172 million from a closing transaction, as evidence that market values exceed book values.

Analysts pressed on how the remaining 2027 debt would be repaid, whether it would rely on a new credit line, and whether more secured debt could be added; management said step 2 would use a mix of asset sales, existing liquidity, and additional secured debt opportunities, not just a revolver. Questions around HSA centered on cash collection weakness, the delayed Florida DPP payments, and confidence in Conifer; management said collections are still in the eighties, Florida has paid about half the DPP money so far, and the rest should arrive soon, with repayments following. Analysts also asked about asset sales, collateral restrictions, and leverage reduction; management said buyers are coming to them, transactions are being negotiated above carrying value, and further deleveraging could come from asset sales rather than equity issuance, which they said is not attractive at the current stock price.